CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.

已取消 10 由 77 发布于 2025/1/22 10:36:25

DOI:10.1182/blood.2023021306
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1182/blood.2023021306
管理员驳回:超时未应助，系统关闭。如求助信息不完整（标题、DOI、原文链接），可以补充后重新发布求助。

American Society of Hematology (ASH)

Abstract：Abstract: CD19-directed chimeric antigen receptor T cells (CAR-T) achieve high response rates in patients with relapsed/refractory mantle cell lymphoma (MCL). However, their use is associate

应助信息

2025-01-22

Book学术机器人

2025/1/22 10:36:25 未找到该文献，机器人已退出，请等待人工下载

2025/1/22 10:36:25 Book学术AI机器人收到请求，开始寻找文献

2025/1/22 10:36:25 已向机器人发送请求

2025-01-22

77 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileyHTT1, a Stearoyl-Acyl Carrier Protein Desaturase Involved Unsaturated Fatty Acid Biosynthesis, Affects Rice Heat Tolerance.